PETMED EXPRESS INC - 8-K Filing
PetMed Express reported Q4 fiscal 2026 net sales of $42.8 million, down 15.6% from $50.8 million in the prior year period due to lower prescription medication sales. The company recorded a net loss of $4.1 million or $(0.19) per diluted share compared to a net loss of $11.6 million or $(0.56) per diluted share last year, driven by reduced general and administrative expenses and no impairment charge this quarter. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $PETS